Every 3 minutes, one person in the United States (U.S.) is diagnosed with blood cancer, as estimated by The Leukemia & Lymphoma Society (LLS). A total number of 176,200 people are expected to be diagnosed with leukaemia, lymphoma or myeloma in 2019. Out of which, 61,780 people are expected to be diagnosed with ...
Find MoreEU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed an...
Find MoreThe U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA). SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN pro...
Find MoreRoche's takes a step- forward to treat Huntington's disease A new drug co-developed by Roche and Ionis Pharmaceuticals can be a potential candidate to treat Huntington's disease. RG6042 which is an antisense oligonucleotide is able to successfully lower down the production of a toxic protein that results in dysf...
Find MoreOvarian Cancer is a type of cancer that starts in Ovaries when the cells in the ovaries keep on dividing abnormally. It can affect either one or both the ovaries. Cancers that start in the ovaries can metastasize to other parts of the body. Ovarian cancer is not a single disease but can be defined as a cluster of d...
Find MoreStemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase...
Find MoreCell Medica receives funds for its cell therapy A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development of CMD-502 off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) cell therapy. The program, su...
Find MoreBiodesix collaborates with MRM for development of mass-spec proteomics Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its iMALDI automated assay technology for quantifying proteins using mass spectrometry. It is done with the goal of enabling precision therapies....
Find MoreRoche signs Icagen in neuro drug discovery deal worth up to USD 274 Million Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders. Icagen receives up to USD 274 million in development and commercial milestones. The duo will work on small molecules...
Find MoreGordon and Betty Moore Foundation gives USD 85 Million to stop delayed, erroneous diagnostics The Gordon and Betty Moore Foundation is putting up money for improving diagnostics. The Foundation focuses on a plethora of areas, including those outside of healthcare, such as environmental conservation. It has an annua...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.